Whole-body VibrationVIBE-RxNCT05097885
Health Benefits of Whole-body Vibration
A study testing Sub Acute Whole Body Vibration Training in people with Whole-body Vibration, run by Augusta University at 1 site in United States.
Trial summary
The overall goals of this pilot investigation are to determine 1) the feasibility of conducting home based WBV studies, and 2) to determine if sub-acute home based WBV can improve a) exercise capacity, b) conduit- and micro- vascular function, and c) skeletal muscle function. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Whole-body Vibration
- What is being tested?
- Sub Acute Whole Body Vibration Training
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Feb 2022to 1 Jan 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Men and women (> 18 yrs old)
- All races
Who cannot join
- <18 years old
- Clinical diagnosis of hepatic, cardiovascular, or renal disease
- Diabetic complications (i.e. macrovascular, microvascular, or autonomic)
- Pregnancy
- Direct vasoactive medications (i.e. nitrates)
Trial locations and contacts
1 site in 1 country.
United States1 site
Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology
Augusta, Georgia, 30912
About this study
Official title: Pilot Investigation on the Health Benefits of Sub Acute (12 Week) Whole-body Vibration Training
The overall goals of this pilot investigation are to determine 1) the feasibility of conducting home based WBV studies, and 2) to determine if sub-acute home based WBV can improve a) exercise capacity, b) conduit- and micro- vascular function, and c) skeletal muscle function.
Read the detailed description
Cardiovascular disease (CVD) is the leading cause of death in the world and many comorbid conditions (i.e. diabetes, obesity) can affect overall CVD risk. There is increasing interest into the role that skeletal muscle health plays in mediating CVD risk, particularly in metabolic disease states (ie. obesity and diabetes). Whole body vibration (WBV) has emerged as an exercise mimetic that may be more tolerable than traditional modes of exercise, such as treadmill walking/running or cycling. Similar to traditional exercise modalities, WBV can elicit beneficial metabolic effects. In fact, a single bout of WBV increases circulating concentrations of IL-6, which correspond with the normalization of glucose and insulin in obese individuals. The proposed pilot investigation will provide the foundation to begin understanding the molecular and physiological mechanisms of how sub-acute WBV can improve overall CVD risk. We hypothesize that home based WBV will decrease CVD risk by improving skeletal muscle and vascular function via a decrease in systemic inflammation.
- Conditions
- Whole-body Vibration
- Being tested
- Sub Acute Whole Body Vibration Training
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sub Acute Whole Body Vibration TrainingOther
Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
| Study group | Role | What they receive |
|---|---|---|
| Sub Acute (12 week) Whole Body Training | Experimental | Not described Receives: Other: Sub Acute Whole Body Vibration Training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in VO2 Peak
change from baseline relative (mL/kg/min) peak oxygen consumption (VO2) during maximal exercise test at 12 weeks
Measured: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
Change in Flow-Mediated Dilation (FMD)
change from baseline brachial artery flow mediated dilation at 12 weeks.
Measured: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
Change in Skeletal Muscle Mitochondrial Function
change from baseline skeletal muscle mitochondrial function at 12 weeks. Measured using Near Infrared Spectroscopy (NIRS). Values are an index of phosphocreatine recovery expressed as a rate constant (min-1)
Measured: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
Change in Pulse Wave Velocity (PWV)
Change from baseline PWV at 12 weeks. Measured by Shygmocor Xcel in m/s.
Measured: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
Change in Post Occlusive Reactive Hyperemia (PORH)
Change from baseline PORH at 12 weeks. Measured by Laser Speckle Contrast Imager (Moor FLPI).
Measured: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
Change in IL-6
change from baseline concentrations of Interleukin 6 (IL-6) obtained via blood draw at 12 weeks.
Measured: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2021
- Study start28 Feb 2022
- Primary completion1 Jan 2028 (estimated)
- Study completion1 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Whole-body VibrationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Augusta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ryan Harris, Augusta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05097885
- Sponsor's protocol ID
- 1818010
- Acronym
- VIBE-Rx
- Status last verified
- Nov 2026
- First submitted
- 15 Oct 2021
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Investigation on the Health Benefits of Sub Acute (12 Week) Whole-body Vibration Training
- ClinicalTrials.gov ID
- NCT05097885
- Acronym / sponsor ID
- VIBE-Rx / 1818010
- Conditions
- Whole-body Vibration
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Augusta UniversityUniversity, hospital or other
- Study start
- 28 Feb 2022 (actual)
- Primary completion
- 1 Jan 2028 (estimated)
- Study completion
- 1 Jan 2029 (estimated)
- First posted
- 28 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall goals of this pilot investigation are to determine 1) the feasibility of conducting home based WBV studies, and 2) to determine if sub-acute home based WBV can improve a) exercise capacity, b) conduit- and micro- vascular function, and c) skeletal muscle function.
Detailed description
Cardiovascular disease (CVD) is the leading cause of death in the world and many comorbid conditions (i.e. diabetes, obesity) can affect overall CVD risk. There is increasing interest into the role that skeletal muscle health plays in mediating CVD risk, particularly in metabolic disease states (ie. obesity and diabetes). Whole body vibration (WBV) has emerged as an exercise mimetic that may be more tolerable than traditional modes of exercise, such as treadmill walking/running or cycling. Similar to traditional exercise modalities, WBV can elicit beneficial metabolic effects. In fact, a single bout of WBV increases circulating concentrations of IL-6, which correspond with the normalization of glucose and insulin in obese individuals. The proposed pilot investigation will provide the foundation to begin understanding the molecular and physiological mechanisms of how sub-acute WBV can improve overall CVD risk. We hypothesize that home based WBV will decrease CVD risk by improving skeletal muscle and vascular function via a decrease in systemic inflammation.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Sub Acute (12 week) Whole Body Training | Experimental | Other: Sub Acute Whole Body Vibration Training |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Men and women (> 18 yrs old)
- All races
Key exclusion criteria (5 listed)
- <18 years old
- Clinical diagnosis of hepatic, cardiovascular, or renal disease
- Diabetic complications (i.e. macrovascular, microvascular, or autonomic)
- Pregnancy
- Direct vasoactive medications (i.e. nitrates)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sub Acute Whole Body Vibration TrainingParticipants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest. | Other | Sub Acute (12 week) Whole Body Training |
Primary outcome
Change in VO2 Peak
Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
change from baseline relative (mL/kg/min) peak oxygen consumption (VO2) during maximal exercise test at 12 weeks
Change in Flow-Mediated Dilation (FMD)
Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
change from baseline brachial artery flow mediated dilation at 12 weeks.
Change in Skeletal Muscle Mitochondrial Function
Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
change from baseline skeletal muscle mitochondrial function at 12 weeks. Measured using Near Infrared Spectroscopy (NIRS). Values are an index of phosphocreatine recovery expressed as a rate constant (min-1)
Change in Pulse Wave Velocity (PWV)
Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
Change from baseline PWV at 12 weeks. Measured by Shygmocor Xcel in m/s.
Change in Post Occlusive Reactive Hyperemia (PORH)
Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
Change from baseline PORH at 12 weeks. Measured by Laser Speckle Contrast Imager (Moor FLPI).
Change in IL-6
Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
change from baseline concentrations of Interleukin 6 (IL-6) obtained via blood draw at 12 weeks.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
Related trials for Whole-body Vibration
Not yet recruiting
Effects of Whole-Body Vibration and Cervical Stabilization With Core Stabilization in Young Adults With Non-Specific Low Back Pain
Nonspecific Low Back Pain
RecruitingPhase 4
Improving Morning Strength and Cognitive Performance Using Caffeine or Whole-body Vibration.
Vibration Therapy, Caffeine
Not yet recruiting
Stair Biomechanics and Vibration Study After ACLR
Anterior Cruciate Ligament Reconstruction (ACLR), Anterior Cruciate Ligament Injury
Active, not recruiting
Hypopressive-Core Stabilization With and Without Whole-Body Vibration in Postpartum Pelvic Girdle Pain
Postpartum Pelvic Girdle Pain
Active, not recruitingEarly Phase 1
Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sub Acute Whole Body Vibration Training in people with Whole-body Vibration, run by Augusta University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in VO2 Peak (time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.